Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.
Max Son, PharmD, MBA
Advertisement
https://www.linkedin.com/in/max-son-pharmd-mba-07538b119/
Articles by Max Son, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
2
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
3
Bridging Science and Reality in Diabetes Care
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5